Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER Adds Antibiotics Specialist For New Senior Advisor Role

This article was originally published in The Pink Sheet Daily

Executive Summary

Robert Guidos returns to FDA from the Infectious Diseases Society of America as senior advisor in the CDER Immediate Office of the Center Director, although the job description seems to indicate a focus beyond antimicrobial issues.

You may also be interested in...



It Takes Two: FDA Reorganizes Office Of Information Management

Taha Kass-Hout has begun his tenure as Chief Informatics Officer, focusing on scientific computing; the agency expects to hire a Chief Information Officer within 60 to 90 days to handle software development and deployment and infrastructure.

FDA’s Potential Black Hole: House Investigates Departure Of Acting Head Of Medical Products Office

Energy and Commerce Committee letter states public information discrepancies raised questions about Leona Brenner-Gati’s status and “the circumstances surrounding her resignation.”

FDA’s Autor Moves To Mylan: Company’s Gain May Also Be Company’s Loss

While Mylan wants Autor to help push quality improvement efforts around the world, her departure from FDA may affect implementation of similar plans at the agency.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS075959

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel